These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

985 related items for PubMed ID: 23996918

  • 21. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, Sudhir K, Smith RS, Cao S, Theodoropoulos K, Cutlip DE, Lansky AJ, Stone GW.
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [Abstract] [Full Text] [Related]

  • 22. Impact of diabetes mellitus on vessel response in the drug-eluting stent era: pooled volumetric intravascular ultrasound analyses.
    Sakata K, Waseda K, Kume T, Otake H, Nakatani D, Yock PG, Fitzgerald PJ, Honda Y.
    Circ Cardiovasc Interv; 2012 Dec; 5(6):763-71. PubMed ID: 23149332
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Intravascular ultrasound analysis of small vessel lesions treated with the Sparrow coronary stent system: results of the CARE II trial.
    Kume T, Waseda K, Koo BK, Yock PG, Botelho R, Verheye S, Whitbourn R, Meredith I, Worthley S, Hai KT, Honda Y, Abizaid A, Fitzgerald PJ.
    Catheter Cardiovasc Interv; 2014 Jan 01; 83(1):19-24. PubMed ID: 23413202
    [Abstract] [Full Text] [Related]

  • 26. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
    Du R, Zhang RY, Zhu ZB, Zhang Q, Hu J, Yang ZK, Yan ZJ, Lv AK, Ding FH, Zhang JS, Shen WF.
    Coron Artery Dis; 2010 May 01; 21(3):175-81. PubMed ID: 20305549
    [Abstract] [Full Text] [Related]

  • 27. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T, Byrne RA, Schuster T, Cuni R, Kitabata H, Tiroch K, Dirninger A, Gratze F, Kaspar K, Zenker G, Joner M, Schömig A, Kastrati A.
    Cardiovasc Revasc Med; 2013 May 01; 14(2):84-9. PubMed ID: 23352095
    [Abstract] [Full Text] [Related]

  • 28. Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.
    Bartorelli AL, Trabattoni D, Almonacid A, Fabbiocchi F, Montorsi P, Galli S, Grancini L, Ravagnani P, Mintz GS, Kaplan AV, Popma JJ, Maehara A.
    Catheter Cardiovasc Interv; 2015 Mar 01; 85(4):544-53. PubMed ID: 25115944
    [Abstract] [Full Text] [Related]

  • 29. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJ, ENDEAVOR IV Trial Investigators.
    JACC Cardiovasc Interv; 2009 Aug 01; 2(8):779-84. PubMed ID: 19695548
    [Abstract] [Full Text] [Related]

  • 30. Comparative assessment of "plaque/media" change on three modalities of IVUS immediately after implantation of either everolimus-eluting bioresorbable vascular scaffold or everolimus-eluting metallic stent in Absorb II study.
    Zeng Y, Cavalcante R, Tenekecioglu E, Suwannasom P, Sotomi Y, Collet C, Abdelghani M, Jonker H, Digne F, Horstkotte D, Zehender M, Indolfi C, Saia F, Fiorilli R, Chevalier B, Bolognese L, Goicolea J, Nie S, Onuma Y, Serruys PW, investigators of Absorb II study.
    Int J Cardiovasc Imaging; 2017 Apr 01; 33(4):441-449. PubMed ID: 28012050
    [Abstract] [Full Text] [Related]

  • 31. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
    Meredith IT, Verheye S, Weissman NJ, Barragan P, Scott D, Valdés Chávarri M, West NE, Kelbæk H, Whitbourn R, Walters DL, Kubica J, Thuesen L, Masotti M, Banning A, Sjögren I, Stables RH, Allocco DJ, Dawkins KD.
    EuroIntervention; 2013 Jul 01; 9(3):308-15. PubMed ID: 23872647
    [Abstract] [Full Text] [Related]

  • 32. Three-year outcomes after revascularization with everolimus- and sirolimus-eluting stents from the SORT OUT IV trial.
    Jensen LO, Thayssen P, Maeng M, Christiansen EH, Ravkilde J, Hansen KN, Kaltoft A, Tilsted HH, Madsen M, Lassen JF, Scandinavian Organization for Randomized Trials With Clinical Outcome SORT OUT IV Investigators.
    JACC Cardiovasc Interv; 2014 Aug 01; 7(8):840-8. PubMed ID: 25086842
    [Abstract] [Full Text] [Related]

  • 33. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G, PRODIGY Investigators.
    JACC Cardiovasc Interv; 2014 Jan 01; 7(1):20-8. PubMed ID: 24332420
    [Abstract] [Full Text] [Related]

  • 34. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL, Xu B, Lansky AJ, Yang YJ, Ma CS, Han YL, Chen SL, Li H, Zhang RY, Fu GS, Yuan ZY, Jiang H, Huo Y, Li W, Zhang YJ, Leon MB, TARGET I Investigators.
    EuroIntervention; 2013 May 20; 9(1):75-83. PubMed ID: 23685298
    [Abstract] [Full Text] [Related]

  • 35. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
    Kimura T, Morimoto T, Natsuaki M, Shiomi H, Igarashi K, Kadota K, Tanabe K, Morino Y, Akasaka T, Takatsu Y, Nishikawa H, Yamamoto Y, Nakagawa Y, Hayashi Y, Iwabuchi M, Umeda H, Kawai K, Okada H, Kimura K, Simonton CA, Kozuma K, RESET Investigators.
    Circulation; 2012 Sep 04; 126(10):1225-36. PubMed ID: 22824435
    [Abstract] [Full Text] [Related]

  • 36. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
    Romaguera R, Brugaletta S, Gomez-Lara J, Pinar E, Jiménez-Quevedo P, Gracida M, Roura G, Ferreiro JL, Teruel L, Gómez-Hospital JA, Montanya E, Alfonso F, Valgimigli M, Sabate M, Cequier A.
    Catheter Cardiovasc Interv; 2015 Mar 04; 85(4):E116-22. PubMed ID: 25380051
    [Abstract] [Full Text] [Related]

  • 37. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 04; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

  • 38. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y, Brugaletta S, Alvarez-Contreras L, Azpeitia Y, Ospino N, Gaido S, Delahanty A, Santos A, Martin-Yuste V, Masotti M, Serruys PW, Windecker S, Sabaté M.
    Catheter Cardiovasc Interv; 2013 Oct 01; 82(4):E428-36. PubMed ID: 23441068
    [Abstract] [Full Text] [Related]

  • 39. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II trial.
    Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, Suttorp MJ, Tijssen JG, Miquel-Hebert K, Veldhof S, Henriques JP, Serruys PW, Piek JJ.
    Circ Cardiovasc Interv; 2009 Aug 01; 2(4):339-47. PubMed ID: 20031737
    [Abstract] [Full Text] [Related]

  • 40. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the Randomized Diabetes and Drug-Eluting Stent (DiabeDES) Intravascular Ultrasound Trial.
    Jensen LO, Maeng M, Thayssen P, Christiansen EH, Hansen KN, Galloe A, Kelbaek H, Lassen JF, Thuesen L.
    Eur Heart J; 2008 Nov 01; 29(22):2733-41. PubMed ID: 18832385
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.